Display options
Cite
Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer. 2010;1(6):597-604doi: 10.1177/1947601910377798.
Felsher, D. W. (2010). MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes & cancer, 1(6), 597-604. https://doi.org/10.1177/1947601910377798
Felsher, Dean W. "MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms." Genes & cancer vol. 1,6 (2010): 597-604. doi: https://doi.org/10.1177/1947601910377798
Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer. 2010 Jun;1(6):597-604. doi: 10.1177/1947601910377798. PMID: 21037952; PMCID: PMC2965623.
Copy Download .nbib Format: NLM
Share it on

Genes Cancer. 2010 Jun;1(6):597-604. doi: 10.1177/1947601910377798.

MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Genes & cancer

Dean W Felsher

Affiliations

  1. Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.

PMID: 21037952 PMCID: PMC2965623 DOI: 10.1177/1947601910377798

Abstract

Tumorigenesis is generally caused by genetic changes that activate oncogenes or inactivate tumor suppressor genes. The targeted inactivation of oncogenes can be associated with tumor regression through the phenomenon of oncogene addiction. One of the most common oncogenic events in human cancer is the activation of the MYC oncogene. The inactivation of MYC may be a general and effective therapy for human cancer. Indeed, it has been experimentally shown that the inactivation of MYC can result in dramatic and sustained tumor regression in lymphoma, leukemia, osteosarcoma, hepatocellular carcinoma, squamous carcinoma, and pancreatic carcinoma through a multitude of mechanisms, including proliferative arrest, terminal differentiation, cellular senescence, induction of apoptosis, and the shutdown of angiogenesis. Cell-autonomous and cell-dependent mechanisms have both been implicated, and recent results suggest a critical role for autocrine factors, including thrombospondin-1 and TGF-β. Hence, targeting the inactivation of MYC appears to elicit oncogene addiction and, thereby, tumor regression through both tumor cell-intrinsic and host-dependent mechanisms.

Keywords: MYC; oncogene addiction; tumorigenesis

References

  1. Cancer Cell. 2002 Dec;2(6):451-61 - PubMed
  2. Mol Cell. 1999 May;3(5):565-77 - PubMed
  3. Nature. 1999 Jul 29;400(6743):468-72 - PubMed
  4. Cell. 2002 May 3;109(3):321-34 - PubMed
  5. Nat Genet. 2000 Jan;24(1):57-60 - PubMed
  6. PLoS Genet. 2008 Jun 06;4(6):e1000090 - PubMed
  7. J Clin Invest. 2006 Apr;116(4):847-52 - PubMed
  8. Clin Cancer Res. 2009 Nov 1;15(21):6479-83 - PubMed
  9. Nat Rev Cancer. 2002 Oct;2(10):764-76 - PubMed
  10. Cancer Cell. 2004 Dec;6(6):577-86 - PubMed
  11. Blood. 2005 Jan 1;105(1):324-34 - PubMed
  12. Blood. 2003 Apr 1;101(7):2797-803 - PubMed
  13. Science. 2002 Jul 5;297(5578):63-4 - PubMed
  14. Science. 2002 Jul 5;297(5578):102-4 - PubMed
  15. Cancer Res. 2008 May 1;68(9):3081-6; discussion 3086 - PubMed
  16. Nat Rev Cancer. 2010 Apr;10(4):301-9 - PubMed
  17. Novartis Found Symp. 2005;265:35-50; discussion 50-4, 92-7 - PubMed
  18. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3645-50 - PubMed
  19. Cold Spring Harb Symp Quant Biol. 2005;70:389-97 - PubMed
  20. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13028-33 - PubMed
  21. Recent Results Cancer Res. 2007;172:5-24 - PubMed
  22. Cell Cycle. 2003 Jul-Aug;2(4):329-32 - PubMed
  23. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1511-6 - PubMed
  24. Oncogene. 2008 Nov 6;27(52):6623-34 - PubMed
  25. Annu Rev Med. 2007;58:267-84 - PubMed
  26. Cancer Cell. 2007 Aug;12(2):108-13 - PubMed
  27. Cancer Metastasis Rev. 2000;19(1-2):121-9 - PubMed
  28. Cancer Res. 2005 Sep 15;65(18):8250-5 - PubMed
  29. Semin Cancer Biol. 2006 Aug;16(4):313-7 - PubMed
  30. Nat Rev Drug Discov. 2006 Sep;5(9):741-54 - PubMed
  31. Nat Cell Biol. 2005 Mar;7(3):295-302 - PubMed
  32. Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 - PubMed
  33. J Clin Invest. 2007 Aug;117(8):2067-74 - PubMed
  34. Nat Cell Biol. 2010 Jan;12(1):54-9; sup pp 1-14 - PubMed
  35. Cancer Cell. 2004 Sep;6(3):241-9 - PubMed
  36. Nat Med. 2001 Feb;7(2):235-9 - PubMed
  37. Genes Dev. 2003 Feb 15;17(4):488-501 - PubMed
  38. PLoS Biol. 2004 Nov;2(11):e332 - PubMed
  39. Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L705-15 - PubMed
  40. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18782-7 - PubMed
  41. Nature. 2004 Oct 28;431(7012):1112-7 - PubMed
  42. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71 - PubMed
  43. Nat Cell Biol. 2010 Jan;12(1):7-9 - PubMed
  44. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9974-9 - PubMed
  45. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):58-63 - PubMed
  46. Cell. 2002 Jan 25;108(2):135-44 - PubMed
  47. Nat Rev Cancer. 2003 May;3(5):375-80 - PubMed
  48. Curr Opin Hematol. 2002 Jul;9(4):303-7 - PubMed
  49. J Cell Biol. 2001 May 28;153(5):1023-34 - PubMed
  50. Oncogene. 2004 Aug 5;23(35):5923-30 - PubMed
  51. Carcinogenesis. 2005 Dec;26(12):2196-206 - PubMed
  52. Cancer Cell. 2007 May;11(5):407-20 - PubMed
  53. Mol Cell. 1999 Aug;4(2):199-207 - PubMed
  54. EMBO J. 2001 Mar 15;20(6):1383-93 - PubMed
  55. Trends Mol Med. 2005 Jul;11(7):316-21 - PubMed
  56. Nucleic Acids Res. 2004 Oct 11;32(18):5368-78 - PubMed
  57. Cancer Cell. 2005 Sep;8(3):197-209 - PubMed
  58. Genes Dev. 2001 Dec 15;15(24):3249-62 - PubMed
  59. Nature. 2007 Jul 26;448(7152):445-51 - PubMed

Publication Types

Grant support